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In SARS‑CoV‑2 infection there is an urgent need to identify patients that will progress to severe 
COVID‑19 and may benefit from targeted treatment. In this study we analyzed plasma cytokines in 
COVID‑19 patients and investigated their association with respiratory failure (RF) and treatment in 
Intensive Care Unit (ICU). Hospitalized patients (n = 34) with confirmed COVID‑19 were recruited into 
a prospective cohort study. Clinical data and blood samples were collected at inclusion and after 2–5 
and 7–10 days. RF was defined as PaO2/FiO2 ratio (P/F) < 40 kPa. Plasma cytokines were analyzed by 
a Human Cytokine 27‑plex assay. COVID‑19 patients with RF and/or treated in ICU showed overall 
increased systemic cytokine levels. Plasma IL‑6, IL‑8, G‑CSF, MCP‑1, MIP‑1α levels were negatively 
correlated with P/F, whereas combinations of IL‑6, IP‑10, IL‑1ra and MCP‑1 showed the best 
association with RF in ROC analysis (AUC 0.79–0.80, p < 0.05). During hospitalization the decline was 
most significant for IP‑10 (p < 0.001). Elevated levels of pro‑inflammatory cytokines were present in 
patients with severe COVID‑19. IL‑6 and MCP‑1 were inversely correlated with P/F with the largest 
AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for 
severe RF and as targets for improved treatment strategies.
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), identified as the causative agent of corona-
virus disease (COVID-19) has quickly spread globally since first reported in December  20191–4. The disease 
usually presents with pneumonia-like signs and  symptoms5. Most people infected with SARS-CoV-2 experience 
mild to moderate disease, but some may suffer severe respiratory failure (RF) and acute respiratory distress 
syndrome (ARDS) in need of mechanical  ventilation5. Clinical management of the disease is mainly supportive 
care, although despite limited evidence, a variety of anti-viral and immunomodulatory therapies have been 
 suggested6–8.
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Severe SARS-CoV-2 infection cause a dysregulated immune response resulting in excessive production of 
inflammatory cytokines and chemokines that contributes to the  pathogenesis9–11. Indeed, viral evasion of initial 
immune responses and a subsequent immunological misfiring causing collateral tissue injury in infected organs 
seem to play major roles in severe COVID-1912–15. Further, evidence suggests that a suboptimal or inappropriate 
T cell response producing pro-inflammatory cytokines may contribute to tissue damage in critically ill COVID-
19  patients16,17.
Lymphopenia, hyperferritinemia and increased D-dimer are associated with severe COVID-1912,18. Reports 
suggests that the hyperinflammation seen in severe COVID-19 may be driven by considerable levels of C-reactive 
protein (CRP) and Interleukin (IL)-6, resembling “cytokine storms” seen in other comparable conditions such 
as during CAR T cell  therapy19–21. Thus, treatment with immunomodulatory therapies targeting IL-6 or IL-1 
receptors could possibly also be of value in COVID-1922–24.
Deeper understanding of the pathogenesis of severe COVID-19 is of major importance for the development 
of targeted immune therapy. There is also an urgent need for prognostic biomarkers in order to early identify 
patients that will progress into critical COVID-19. Inflammatory mediators are operating in a complex network 
and the aim of the present study was to map and characterize this network, including interleukins, interferons, 
chemokines and growth factors, in plasma collected from patients with various severity of confirmed COVID-19. 
We explored their potential as prognostic biomarkers for RF, need of treatment in an intensive care unit (ICU) 
and their relation to routine biochemical and hematological markers of hyperinflammation.
Methods
Study design and population. Adult patients (≥ 18 years old) hospitalized between March 6th and April 
14th with confirmed SARS-CoV-2 infection by positive real-time polymerase chain reaction test targeting the 
E-gene of SARS-CoV-2 were consecutively recruited from Oslo University Hospital, Ullevål and Drammen Hos-
pital, Vestre Viken Hospital Trust, Norway to a multi-center prospective cohort study (Norwegian SARS-CoV-2 
study; NCT04381819). Recent publications report on patients included in the same cohort  study25–28. Clinical 
information and laboratory samples were for most cases collected within 48 h after hospitalization. Peripheral 
blood was drawn at inclusion, day 2–5 and day 7–10 during hospitalization.
Data collection. Clinical and routine diagnostics were abstracted from electronic medical records using a 
modified version of the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC, 
isaric.tghn.org) /World Health Organization (WHO) Clinical Characterization Protocol (CCP) and entered into 
a secure web-based REDCap database (Research Electronic Data Capture, Vanderbilt University, TN, hosted by 
University of Oxford, UK).
Clinical outcomes. Clinical outcomes were: (1) development of respiratory failure (RF) during hospitaliza-
tion defined as an arterial partial pressure of oxygen  (PaO2) to fraction of inspired oxygen  (FiO2) ratio (P/F) of 
less than 40 kPa (< 300 mm Hg), corresponding to the threshold-value for ARDS by the Berlin  definition29, and 
(2) need of treatment in ICU. Where  PaO2 was not available from the records, PaO2 values were calculated from 
 SaO230.
Ethical considerations. Informed consents were obtained from all patients or patients’ family members. 
The study was approved by the Regional Committee for Medical and Health Research Ethics in South-Eastern 
Norway (reference number 106624, clinicaltrial.gov NCT04381819). All methods were performed in accordance 
with the relevant guidelines and regulations.
Sample processing. Peripheral blood was collected into 4 mL  Vacuette® (Greiner bio-one International) 
containing EDTA to avoid coagulation. Samples were immediately stored on ice, processed within 30 min and 
plasma were isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma were immediately frozen at − 80 °C in 
several aliquots and thawed only once prior to multiplex analysis.
Multiplex analyses. EDTA plasma samples from 34 hospitalized patients (Drammen hospital [n = 16] 
and Oslo University Hospital Ullevål [n = 18] were analyzed using a multiplex cytokine assay (Bio-Plex Human 
Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc., Hercules, CA) containing the following interleukins, 
chemokines and growth factors: Interleukin (IL)-1β, IL-1 receptor antagonist (IL1-ra), IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin/CXCL11, basic fibroblast growth fac-
tor (bFGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor 
(GM-CSF), interferon (IFN)-γ, interferon-inducible protein (IP-10)/CXCL10, monocyte chemotactic protein 
(MCP-1)/CCL2, macrophage inflammatory protein (MIP)-1α/CCL3, MIP-1β/CCL4, platelet derived growth 
factor-BB (PDGF-BB), regulated upon activation T cell expressed and secreted (RANTES)/CCL5, tumor necro-
sis factor (TNF), and vascular endothelial growth factor (VEGF). The samples were analyzed on a Multiplex 
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Analyzer (Bio-Rad Laboratories) according to instructions from the manufacturer. Six of the 27 analytes were 
not detectable in more than 30% of the samples and were therefore excluded for further analysis (IL-5, IL-10, 
IL-15, GM-CSF, VEGF and INF-γ). A limited number of samples were below the lower detection limit and in the 
statistical analyses these were given a random number below the detection limit. The normal reference values for 
this 27-plax assay are indicated with red lines in Fig. 131.
Statistical analysis. Non-parametric testing was used to investigate differences between two or more 
groups. Mann–Whitney U test was used to compare two independent groups while Kruskal–Wallis was used 
comparing three groups. Friedman’s test was applied on longitudinal samples, investigating changes from base-
line, day 2–5 and day 7–10. p values were considered significant when < 0.05. Due to the explorative nature of 
the study the statistical analyses were not corrected for multiple testing. The area under the receiver operating 
characteristics (ROC) curve (AUC) was estimated for patients with or without RF. The optimal cut-off value 
was defined as the value with the highest Youden’s Index. Correlations were calculated using Spearman rank 
correlation coefficient. Statistical analysis was performed by SPSS statistical software (Macintosh version 26.0, 
IBM, Armonk, NY, USA).
Results
Patient characteristics. Table  1 displays demographic and clinical characteristics of the COVID-19 
patients included in this study (n = 34). Median age was 58 years and 74% were men. Twenty-one of the 34 
patients developed RF reflected in a P/F ratio < 40 kPa. Ten patients, all with RF, were treated in the ICU includ-
ing four patients that died during hospitalization. RF patients were mostly men (86%), had higher leucocyte 
count and higher D-dimer, ferritin, C-reactive protein (CRP) and bilirubin levels compared to the non-RF 
group. In contrast, the median number of days between the first onset of symptoms and admission to hospi-
tal were comparable and there were no differences in age, previous co-morbidities or kidney function (eGFR) 
between the two groups.
Elevated cytokine levels in COVID‑19 patients with respiratory failure and in ICU. To inves-
tigate a potential dysregulated immune response in critically ill COVID-19 patients we analyzed plasma levels 
of 27 cytokines. All of the 21 cytokines with reliably detectable plasma levels (see “Methods” section), showed 
higher levels in COVID-19 patients than in healthy controls (red line Fig.  1) obtained from Hennø et  al.31. 
Nine mediators (IL-1ra, IL-2, IL-4, IL-6, FGF basic, IP-10, MCP-1, MIP-1α and TNF) were significantly higher 
in the RF group compared to non-RF patients at admission (Fig.  1) and IL-6 (0.50, p < 0.01), G-CSF (0.55, 
p < 0.01), MCP-1 (0.45, p < 0.05) and MIP-1α (0.49, p < 0.05) levels showed a negative correlation with P/F ratio. 
We also investigated the relationship between RF and cytokine levels by ROC analysis (Fig. 2). MCP-1 (0.79) and 
IL-6 (0.77) and the combinations of MCP-1/IL-6 (0.79) and MCP-1/IL-1ra 1 (0.81) demonstrated the largest, 
although modest, areas under the curve (AUC) (Fig. 2B). The optimal cut-off values (the highest Youden’s Index) 
for the cytokines are displayed in Table 2. The calculated values for IL-6 and MCP-1 in predicting RF were 10 pg/
mL and 20 pg/mL respectively.
Further, when stratifying the patients dependent on the need of treatment in an ICU compared to regular 
ward we found significant higher levels of altogether 13 cytokines (IL-1ra, IL-2, IL-4, IL-6, IL-7, IL-8, IL-17A, 
FGF basic, G-CSF, IP-10, MCP-1, MIP-1α and TNF) in ICU compared to non-ICU patients (Fig. 3).
Relationship between biochemical and hematological markers of inflammation and cytokine 
levels in patients with COVID‑19. Since several cytokines were significantly elevated in COVID-19 
patients with RF, we further investigated if any of these cytokines were associated with other biochemical and 
hematological markers of inflammation (Fig. 4). IL-1ra, IL-6, IL-8, G-CSF, MCP-1, IP-10, MIP-1α showed a 
positive correlation with ferritin, whereas there were no correlations found between cytokines and leukocyte 
count, CRP or D-dimer. Only IL-9 showed a positive correlation with bilirubin.
Dynamic changes in cytokine levels in COVID‑19 patients during hospitalization. Cytokine 
plasma levels were analyzed at several time points during hospitalization to explore their dynamics in COVID-
19 (Supplementary Figure S1). Of the 15 patients with available longitudinal samples three were treated in ICU 
for the whole period, one was transferred to ICU at day 2–5, whereas another two patients were transferred to 
ICU after 7–10 days. Of the ten cytokines that were elevated in RF patients at baseline, only IL-1ra, MIP-1α, 
G-CSF and IP-10 displayed significant changes during follow-up (Fig. 5). Overall, especially IP-10 levels were 
reduced for the majority of patients irrespective of P/F values at the last time point (p < 0.001). Of note, for two of 
the three patients that were referred to ICU during hospitalization, there was a corresponding increase in plasma 
IL-1ra, MIP-1α, G-CSF and IP-10 levels.
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Figure 1.  Cytokines at admission in COVID-19 patients with respiratory failure. Twenty-one cytokines had 
detectable levels in plasma from COVID-19 patients at admission to hospital. The levels of IL-1ra, IL-2, IL-4, 
IL-6, FGF basic, MCP-1, MIP-1α and TNF were significantly higher in patients with RF (n = 19) compared to 
non-RF patients (n = 12). For three patients baseline samples were not available and these were excluded from 
the analysis set. Patients that died during hospitalization (n = 4) are shown in orange circles. Red lines indicate 
reference values by Hennø et al.31. Groups were compared using Mann U Whitney test, significance * < 0.05.
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Discussion
We present data from a Norwegian COVID-19 patient cohort where plasma cytokine levels at admission and 
follow up during the first ten days of hospitalization were related to disease severity expressed as RF and/or 
need of ICU treatment or signs of hyperinflammation in peripheral blood. We show that a broad network of 
pro-inflammatory cytokines is elevated in plasma from patients with COVID-19, especially pronounced in 
patients with severe RF and even more obvious in patients with need of ICU care. IL-6 and MCP-1 seemed to 
be of particular interest since they were markedly elevated in patients with RF, significantly inversely correlated 
with P/F ratio and showed modest, still the largest AUC in ROC analyses. Thus, our data demonstrates a marked 
dysregulation of the cytokine network in COVID-19 patients and for MCP-1 and IL-6, the levels were strongly 
correlated with the degree of RF.
Although inflammation is a protective process to clear any foreign pathogen, excessive inflammation can cause 
severe collateral tissue damage. Our findings of elevated cytokine levels in patients with RF, ICU and hyperinflam-
mation are consistent with earlier reports of SARS-CoV10, SARS-CoV-213,23,32 and for ARDS  alone33. The cytokine 
release syndrome has been suggested as an important cause of ARDS and RF in COVID-19  patients13,22,23,34. We 
demonstrated increased levels of a wide range of inflammatory cytokines in these patients such as IL-1ra, IL-6, 
IP-10, G-CSF, MCP-1, MIP-1α and TNF, all rapidly released upon innate immune activation and important 
for shaping the adaptive immune response and induce T cell  activation35. This is supported by data from the 
same cohort showing that COVID-19 patients with poor outcome and cardiac involvement are characterized 
by activated and exhausted T  cells26. Together this may reflect systemic cytokine activation in the RF patients, 
contributing to immunopathology and pulmonary dysfunction in COVID-1914,15,23. Of these cytokines, IL-6 
and MCP-1 were consistently associated with RF. It has recently been suggested that IL-6, IL-1ra, IP-10 and 
MCP-3 could serve as predictive markers for disease progression in COVID-1932,36–38. Several studies have 
suggested a link between high IL-6 levels and disease severity in COVID-19, indicating that IL- 6 is involved 
Table 1.  Patient characteristics. Data are given as median (range), n (%). Significance indicated with *p < 0.05, 
#p < 0.01, §p < 0.001. a One patient who died was in need of ICU but was not transferred due to high age.
Total (n = 34) RF (n = 21) Non-RF (n = 13) ICU (n = 10) Non-ICU (n = 24)
Age 58 (27–91) 54 (45–91) 63 (27–91) 58 (46–91) 58 (27–91)
Sex, male 25 (74) 18 (86)* 7 (54) 9 (90) 16 (68)
RF 21 (62) 21 (100) – 10 (100) 11 (46)
ICU 11 (32) 10 (48) 0 10 (100)a –
Days (symptom to hospital admis-
sion) 10 (2–38) 10 (2–37) 10 (3–38) 9 (2–37) 10 (3–38)
Co-morbidities
Hypertension 6 (15) 2 (10) 4 (30) 0 (0) 6 (26)
Diabetes 4 (12) 2 (10) 2 (15) 1 (10) 3 (13)
Chronic heart disease 8 (24) 4 (19) 4 (31) 4 (40) 4 (17)
Chronic lung disease 1 (3) 1 (5) 0 1 (10) 0
Chronic kidney disease 4 (12) 2 (10) 2 (15) 2 (20) 2 (8)
Symptoms and O2 therapy
Fever 30 (88) 18 (86) 12 (92) 8 (80) 22 (92)
Cough 28 (82) 17 (81) 11 (85) 8 (80) 20 (83)
Sputum 11 (32) 8 (38) 3 (23) 2 (20) 9 (38)
Sore throat 10 (29) 5 (24) 5 (39) 1 (10)* 9 (38)
Dyspnoae 22 (65) 16 (76) 6 (46) 8 (80) 14 (58)
Respiratory rate > 22 (breaths per 
min) 22 (65) 15 (71) 7 (54) 9 (82) 12 (52)
PaO2 /FiO2 ratio 39 (8–66) 32 (8–45)§ 46 (32–66) 28 (8–40)# 43 (23–66)
Oxygen therapy 28 (82) 20 (95)* 8 (62) 10 (100) 18 (75)
Laboratory
Leucocytes (× 109/L) 5.8 (2.6–19.0) 7.2 (3.8–19.0)# 4.9 (2.6–8.1) 9.3 (3.8–19.0)* 5.4 (2.6–12.0)
Lymphocytes (× 109/L) 1.1 (0.3–2.1) 1.0 (0.5–1.7) 1.2 (0.3–2.1) 1.1 (0.5–1.5) 1.1 (0.3–2.1)
Platelets (× 109/L) 192 (110–611) 201 (136–611) 186 (110–302) 192 (161–611) 193 (110–350)
Haemoglobin (g/dL) 13.4 (8.5–17.9) 13.6 (8.5–17.9) 13.2 (9.8–15.2) 12.8 (8.5–17.9) 13.4 (9.8–15.6)
D-dimer (mg/L) 0.80 (0.30–4.10) 1.2 (0.48–4.10)* 0.55 (0.30–4.0) 1.60 (0.71–4.10)* 0.76 (0.30–4.0)
Ferritin (μg/L) 814 (105–2893) 1114 (178–2893)§ 455 (105–1609) 1226 (178–2893) 747 (105–2777)
C-reactive protein, (mg/L) 67 (3–448) 117 (23–448)* 46 (3–191) 151 (44–448)# 47 (3–196)
LDH (U/L) 322 (118–561) 350 (146–561) 274 (118–354) 441 (146–561)* 283 (118–479)
eGFR (mL/min/1.73 m3) 86 (13–164) 86 (23–164) 79 (13–113) 81 (23–164) 91 (13–120)
Bilirubin total, (μmol/L) 10 (3–17) 11 (8–17)* 8 (3–17) 12 (8–17) 9 (3–17)
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Figure 2.  ROC analyses of cytokines in patients with respiratory failure. The receiver operating characteristic 
(ROC) curve was calculated comparing baseline plasma (A) cytokine levels and (B) combination of cytokine 
levels in RF vs non-RF patients with calculated sensitivity and specificity. Area under the ROC curve (AUROC) 
p values were < 0.05. Cytokines for ROC analyzes were selected on whether they showed significant difference 
between the two groups (Fig. 1).
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Table 2.  Prediction of respiratory failure by plasma cytokine analyses.
Sensitivity % 95% CI Specificity % 95%CI Optimal cut-off (pg/mL)
IL-1ra 74 51–88 75 47–91 474
IL-6 95 75–100 58 32–81 10
MCP-1 74 51–88 83 55–97 20
IP-10 58 36–77 83 55–97 1849
FGF basic 47 27–68 100 75–100 31
Figure 3.  Cytokine levels in COVID-19 patients in ICU compared to non-ICU. Cytokine levels in patients with 
(n = 9) or without (n = 22) treatment in ICU. For three patients baseline samples were not available and these 
were excluded from the analysis set. Groups were compared using Mann U Whitney test, significance < 0.05.
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Figure 4.  Correlation between biochemistry/hematology parameters and Cytokines. Table displaying Rho 
values from correlation analysis. Plasma cytokine levels were correlated to leukocyte count  (109/L, n = 29), 
CRP (mg/L, n = 29), D-dimer (n = 23), ferritin (μg/L, n = 29) and Bilirubin (μmol/L, n = 25). Correlations were 
calculated with Spearman correlation coefficient. Blue color indicates a positive correlation while red represents 
a negative correlation. Significant correlations are displayed with *. Significance * < 0.05, ** < 0.01.
Figure 5.  Longitudinal cytokine levels in COVID-19 patients during hospitalization. Measurement of plasma 
cytokine levels at day 1 (n = 15), day 2–5 (n = 15) and day 7–10 (n = 15) after hospitalization. Scatter plot 
displaying individual values of longitudinal data showing a significant change in the levels of four cytokines. 
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in down-regulation of HLA-DR and lymphopenia, contributing to the sustained cytokine levels seen in severe 
COVID-1911,15. Data on MCP-1 levels in severe SARS-CoV suggest that secretion of MCP-1 is associated with 
lung  injury10,12,39, and our finding indicates that this macrophage activating chemokine could play a pathogenic 
role in COVID-19 associated RF. The calculated cut-off value of IL-6 for predicting RF (10 pg/mL) in our study 
was lower than the predictive value of 65 pg/mL in a study of a combined evaluation and validation  cohort37 and 
in another study predicting mortality (86 pg/mL)40. The different values could be due to different definitions and 
measurements of RF. Herold et al., used the need for mechanical ventilation as a measure of  RF37 whereas P/F 
ratio less than 40 kPa was defined as RF in our study. These studies, including ours have a relatively low number 
of patients that progress to severe disease, and larger cohorts are needed to validate the predictive cut-off values 
for IL-6 for various clinical outcomes.
In addition to IL-6 and MCP-1, we show that the combinations of these cytokines with IL-1ra and IP-10 
were equally good as predictors of COVID-19 severity. IL-1ra circulates in much higher levels than IL-1 itself, 
is involved in NLRP3 inflammasome activation and has been suggested as a reliable marker of IL-1 activity in 
COVID-19  disease41. IP-10 is an important mediator of monocyte/macrophage-induced T cell activation also 
proposed to play a role in COVID-19  pathogenesis36,42,43. IP-10 is markedly elevated both in blood and lung 
tissue from SARS-patients44. We found that the marked elevation of IP-10 levels correlating with COVID-19 
severity declined throughout hospitalization, in line with a recently published study and in previous studies in 
 SARS45. Interestingly, there was a corresponding increase in not only IP-10, but also IL-1ra, MIP-1a and G-CSF 
in patients transferred to ICU during hospitalization indicating a worsening of clinical condition.
Despite that plasma inflammatory cytokines are highly heterogeneous with a wide range of biological func-
tions they serve as valuable biomarkers in the diagnosis, management and prognosis of several inflammatory 
 diseases46. We suggest that IL-6 and MCP-1 should be added to the list of candidate markers for disease predic-
tion in COVID-19 patients with RF, as well as be further explored as targets for immune therapy with cytokine 
antagonists. Still, although the levels of pro-inflammatory cytokines seem to be increased in patients with severe 
COVID-19, the correlation between cytokines and clinical stage are far from consistent. Early reports argue that 
lower levels of IL-6 were observed in severe COVID-19, inconsistent with a true cytokine  storm47–49. However, 
emerging evidence shows that IL-6 seems to play a central role in cytokine storm reflecting severe COVID-
1937,38,50. Interestingly, most of the patients in our study also lack some of the clinical hallmarks of systemic 
cytokine storms like hypotension, capillary leakage syndrome and multi-organ failure indicating that a true 
cytokine storm still is relatively rare in COVID-19. This is further strengthened by the recent findings of mean 
IL-6 levels significant lover in COVID-19 with ARDS than bacterial sepsis with  ARDS51. This suggests that 
only a minority of patients will benefit from specific anti-cytokine treatment. Thus, accurate patient selection 
is necessary, as cytokine blockers are potent drugs with risk of adverse  reactions52,53. However, it would be of 
great importance to characterize and predict which patients that will progress to severe COVID-19 and could 
benefit from targeted therapy.
Several studies suggest that IL-6 may predict the risk of severe disease and  mortality37,40. Beneficial effects of 
IL-6 inhibitors have also been shown in large observational  studies24,54,55. Data from well-designed randomized 
clinical trials are critical to confirm a beneficial effect. Preliminary results from a clinical trial (NCT04320615) 
indicate that IL-6 inhibitor treatment could shorten time to discharge although there were no effects on mortal-
ity and clinical  status56. Although our study doesn’t have enough numbers of patients to identify biomarkers for 
severity, our findings of the association between IL-6, IP-10, IL-1ra and RF in COVID-19 provides a foundation 
for further studies investigating their predictive value for RF.
There are some limitations in this study with a small sample size, especially for longitudinal samples where 
plasma could not be obtained on all time-points for several patients due to logistic challenges. Thus, small differ-
ences may not be detected or could give false positive results indicating that the results and significance should 
be interpreted with caution. The results from the ROC analyses were also all modest, therefore cut-off values and 
the cytokines predictive value must be interpreted with caution. In addition, associations may not necessarily 
reflect any causal relationship. Finally, plasma isolated from peripheral blood may not fully reflect the immune 
responses taking place in the infected tissue and more unbiased approaches will aid the characterization of the 
hyperinflammatory milieu in which several studies are  emerging14,57.
In conclusion, we show that patients with RF, admitted to ICU and with biochemical signs of inflamma-
tion have increased cytokine production indicating a hyperinflammatory response, and increased level of IL-6, 
MCP-1, IP-10 and IL-1ra was associated with RF. Specific prognostic biomarkers can facilitate rapid detection 
of critically ill COVID-19 patients and aid in targeted treatment strategies, resulting in improved outcome of 
disease. Although we did not find convincing evidence of a true cytokine storm, especially combinations of IL-6 
and MCP-1 may be further explored as potential biomarkers in severe COVID-19 infection.
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